We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Immunoassay Monitors Parasite Persistence in Chagas Disease

By LabMedica International staff writers
Posted on 01 Mar 2018
Print article
Image: The sciFLEXARRAYER system is an ultra-low volume dispensing systems (Photo courtesy of SCIENION).
Image: The sciFLEXARRAYER system is an ultra-low volume dispensing systems (Photo courtesy of SCIENION).
The Trypanosoma cruzi parasite is the causative agent of Chagas disease, and infects about six million individuals in more than 20 countries. Monitoring parasite persistence in infected individuals is of utmost importance to develop and evaluate treatments to control the disease.

In the absence of specific clinical signs, several techniques have been proposed to evaluate the treatment efficacy of Chagas disease including serological assays and the detection of the parasite in blood by polymerase chain reaction (PCR). Among these techniques, PCR has shown promising results for assessment of anti-parasitic therapy failure, but not therapy efficacy.

An international team of scientists led by those at INFYNITY BIOMARKERS SAS (Lyon, France) designed a multiplex serology assay, an array of fifteen optimized T. cruzi antigens, to evaluate antibody diversity in 1,654 serum samples from chronic Chagas patients. This included 1,199 patients without self-reported previous treatment or 455 with a history of benznidazole (BZN) treatment. Among these treated patients, the reported treatment history ranged from one year to ten years prior to accrual.

The assay used in the study was an extended version of the MultiCruzi confirmatory assay. The team used the sciFLEXARRAYER system (SCIENION, Berlin, Germany) to print fifteen T. cruzi antigens, selected for their proven immunogenic properties, in duplicates in each well of a 96-well plate. The coating of antigens and the enzyme-linked immunosorbent assay (ELISA) were carried out. The target-capture real-time (RT) PCR assay used in this study was developed based on the PCR method that targets satellite T. cruzi DNA. DNA extraction and concentration was improved through use of a target capture step that employed magnetic beads coated with T. cruzi-specific 20-mer capture oligonucleotides.

The scientists found one specific antibody response (antibody 3, Ab3) showed a strong correlation with T. cruzi parasite persistence as determined by T. cruzi PCR positive results. High and sustained Ab3 signal was strongly associated with PCR positivity in untreated patients, whereas significant and progressive decline in Ab3 signals was observed in BZN-treated patients who cleared parasitemia based on blood PCR results. Ab3 was reactive in 98% of T. cruzi seropositive (PCR negative and PCR positive) samples.

The authors concluded that Ab3 is a new surrogate biomarker that strongly correlates with parasite persistence in chronic and benznidazole-treated Chagas patients. They hypothesized that Ab3 is induced and maintained by incessant stimulation of the immune system by tissue-based and shed parasites that are not consistently detectable by blood based PCR techniques. Hence, a simple immunoassay measurement of Ab3 could be beneficial for monitoring the infectious status of seropositive patients. The study was published on February 9, 2018, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:
INFYNITY BIOMARKERS
SCIENION

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Piezoelectric Micropump
Disc Pump
New
Auto Clinical Chemistry Analyzer
cobas c 703

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.